RxSight Inc. (RXST)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight Q2 Earnings Call Highlights
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.08 per share a year ago.
RxSight Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 601 | $4,560.32 | $3,593.98 | -$966.34 | -21.19% |
| NA Nizar Araji National Bank Of Canada /FI/ | 405 | $5,260.99 | $2,535.3 | -$2,725.69 | -51.81% |
 Point72 Asset Management LP Point72 Asset Management LP | 778,252 | $7.87M | $5.36M | -$2.51M | -31.87% |
 Joseph Castro Nuveen LLC | 125,778 | $1.02M | $754,039.11 | -$264,547.59 | -25.97% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 48 | $295.68 | $288.72 | -$6.96 | -2.35% |
RxSight Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DS David Saxon Needham | 986.98 | $6,689.41 | $5,967.58 | -$721.83 | -10.79% |
 Craig Bijou B of A Securities | -11,922.92 | $67,006.82 | $72,089.56 | -$5,082.74 | -7.59% |
RxSight Inc. (RXST) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RxSight Inc. ever had a stock split?
RxSight Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Aziz Mottiwala CEO | NASDAQ (NMS) Exchange | 78349D107 CUSIP |
| US Country | 461 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
RxSight, Inc. stands out as a pivotal figure in the medical device industry, focusing principally on the vital phases of research, development, manufacturing, and global sales of innovative light adjustable intraocular lenses (LAL) used predominantly in cataract surgery. This commercial-stage company, exercising its operations both within the United States and internationally, carries the legacy of revolutionizing post-surgery vision enhancement for patients undergoing cataract procedures. Initially established under the name Calhoun Vision, Inc., the company transitioned to RxSight, Inc. in February 2017, marking a significant rebranding phase centered around its groundbreaking products and technologies. Since its incorporation in 1997, RxSight, Inc., with its corporate headquarters nestled in Aliso Viejo, California, has dedicatedly served the specialist needs of cataract doctors and their patients, striving to deliver tailored visual outcomes post-cataract surgery.
Products and Services
The comprehensive offerings of RxSight, Inc. are encapsulated within its signature RxSight system, a testament to the company's commitment to innovation and customized patient care in cataract surgery recovery.
- RxSight Light Adjustable Lens: At the core of the RxSight system lies the Light Adjustable Lens, a marvel of medical technology designed with a special photosensitive material. This cutting-edge lens uniquely stands out for its ability to change shape and power, thereby permitting post-operative adjustments to align with the patient’s visual needs. Such a feature empowers patients with the possibility of achieving optimally tailored visual outcomes, a significant leap forward from the conventional intraocular lenses.
- RxSight Light Delivery Device: Complementing the functionality of the Light Adjustable Lens is the RxSight Light Delivery Device, a sophisticated, office-based UV light treatment apparatus. Engineered to deliver UV light in a meticulously programmed pattern, this device is crucial for modifying the Light Adjustable Lens according to the specific visual correction required. The process encapsulates the essence of RxSight, Inc.'s innovation by enabling on-demand adjustments to the lens, thus facilitating the attainment of the desired vision post-cataract surgery.
